Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Form 483
Pharma
Daiichi, Eisai, Granules—Fierce Pharma Asia
Merck and Daiichi's HER3 ADC delivered a positive phase 3 result. An FDA document details shortfalls at a Granules plant in India. Plus more.
Angus Liu
Sep 20, 2024 10:16am
Granules receives Form 483 over poor document controls and more
Sep 19, 2024 10:11am
Akeso-Summit, BIOSECURE, Candid and more—Fierce Pharma Asia
Sep 13, 2024 8:53am
FDA issues Form 483s to Japanese, Indian drugmakers
Sep 10, 2024 8:50am
Sanofi, DualityBio, UCB—Fierce Pharma Asia
Aug 30, 2024 8:05am
API maker Global Calcium gets hit with FDA Form 483
Aug 29, 2024 11:52am
